TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35277313

Group type: EXPERIMENTAL
Intervention: Participation in WIC into the third year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participation in WIC in the first year only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Introduced to sugar-sweetened beverages in the first year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breastfed longer
Number of subjects: 0
Study: 35277335

Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement project designed to improve delivery of comprehensive women's health care
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Creation of separate clinical spaces for women
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Education to change patient harassing behavior
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Assessment of environments of care
Number of subjects: 69
Study: 35277389

Group type: EXPERIMENTAL
Intervention: Third dose of CoronaVac vaccine
Number of subjects: 796
Study: 35277410

Group type: EXPERIMENTAL
Intervention: Community-based performance arts programme (Stroke Odysseys)
Number of subjects: 75
Study: 35277577

Group type: EXPERIMENTAL
Intervention: High CAD PRS
Number of subjects: 3800

Group type: COMPARATOR
Intervention: Low CAD PRS
Number of subjects: 3800

Group type: EXPERIMENTAL
Intervention: High CAD PRS (Statins)
Number of subjects: 3800

Group type: COMPARATOR
Intervention: Low CAD PRS (Statins)
Number of subjects: 3800

Group type: EXPERIMENTAL
Intervention: High CAD PRS (Non-statin)
Number of subjects: 3800

Group type: COMPARATOR
Intervention: Low CAD PRS (Non-statin)
Number of subjects: 3800
Study: 35277733

Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide (NT-proBNP)
Number of subjects: 2522

Group type: EXPERIMENTAL
Intervention: high-sensitive Troponin T (hsTnT)
Number of subjects: 2522
Study: 35277935

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact survey
Number of subjects: 2950
Study: 35278000

Group type: EXPERIMENTAL
Intervention: Targeted next-generation sequencing using the new gene panel TGP-T-LBL with 84 candidate genes
Number of subjects: 46

Group type: COMPARATOR
Intervention: Previous gene panel with 80 candidate genes
Number of subjects: 46
Study: 35278571

Group type: EXPERIMENTAL
Intervention: V-index during AF
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: QTc
Number of subjects: 1711
Study: 35278825

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 208
Study: 35278845

Group type: EXPERIMENTAL
Intervention: Comprehensive genomic profiling (CGP) using Oncomine Comprehensive Assay Version 3, ThermoFisher
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Comprehensive genomic profiling (CGP)
Number of subjects: 134
Study: 35278876

Group type: EXPERIMENTAL
Intervention: Early echocardiography performed by treating physicians
Number of subjects: 1359

Group type: COMPARATOR
Intervention: No echocardiography
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Early echocardiography in cardiac disease patients
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Early echocardiography
Number of subjects: 1359
Study: 35279084

Group type: EXPERIMENTAL
Intervention: RBX2660
Number of subjects: 142

Group type: COMPARATOR
Intervention: Historical control (standard-of-care antibiotics)
Number of subjects: 142
Study: 35279088

Group type: EXPERIMENTAL
Intervention: STOP&WATCH instrument for early recognition of changes in resident condition
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: ISBAR instrument for structured communication
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: INTERCARE nurses providing on-site geriatric support
Number of subjects: 573
Study: 35279143

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg single-dose primaquine
Number of subjects: 157
Study: 35279152

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (standard of care chemotherapy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MYC/MAX dimerization inhibitor (10058-F4)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single cell RNA sequencing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Liquid biopsy CTC-derived xenograft (CDX) models
Number of subjects: 10
Study: 35279271

Group type: EXPERIMENTAL
Intervention: 200 mg pembrolizumab intravenously every 3 weeks for 6 months (eight cycles)
Number of subjects: 17
Study: 35279417

Group type: EXPERIMENTAL
Intervention: Nutritional status assessed by the CONUT score
Number of subjects: 14849

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 14849
Study: 35279805

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 5

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 5

Group type: COMPARATOR
Intervention: Guselkumab
Number of subjects: 5

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 5

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 5
Study: 35279811

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²) administered as four weekly intravenous infusions
Number of subjects: 25
Study: 35280363

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg) combined with paclitaxel (135 mg) and cisplatin as neoadjuvant therapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT) as the standard treatment under NCCN guidelines.
Number of subjects: 0
Study: 35280476

Group type: EXPERIMENTAL
Intervention: ECMO support
Number of subjects: 65
Study: 35280494

Group type: EXPERIMENTAL
Intervention: Robotic low anterior resection (RLAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transanal total mesorectal excision (TaTME)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both RLAR and TaTME
Number of subjects: 0
Study: 35280654

Group type: EXPERIMENTAL
Intervention: ELIGARD
Number of subjects: 106
Study: 35280720

Group type: EXPERIMENTAL
Intervention: Extraperitoneal laparoscopic extended lymph node dissection (LND) during extraperitoneal laparoscopic radical nephroureterectomy (RNU)
Number of subjects: 39
Study: 35280786

Group type: EXPERIMENTAL
Intervention: whole-body PET/CT scan 40-60 min postinjection
Number of subjects: 19
Study: 35280802

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) regimens
Number of subjects: 373

Group type: COMPARATOR
Intervention: SOXA (apatinib in combination with S-1 and oxaliplatin) cohort
Number of subjects: 373
Study: 35280910

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Berlin Definition of ARDS
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Altitude-PaO
Number of subjects: 1221
Study: 35281074

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etanercept (ETA)
Number of subjects: 20
Study: 35281856

Group type: EXPERIMENTAL
Intervention: Vismodegib (150 mg orally once a day for a 21-day cycle)
Number of subjects: 23
Study: 35281992

Group type: EXPERIMENTAL
Intervention: Automated atlas-based quantification procedure (AQP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual delineation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AQP
Number of subjects: 0
Study: 35282037

Group type: EXPERIMENTAL
Intervention: Apatinib mesylate (500 mg qd) plus pemetrexed (500 mg/m2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Apatinib mesylate plus pemetrexed
Number of subjects: 21
Study: 35282086

Group type: EXPERIMENTAL
Intervention: Apatinib plus 5-fluorouracil (5-FU)
Number of subjects: 16
Study: 35282136

Group type: EXPERIMENTAL
Intervention: Hetrombopag (5 mg orally once daily for up to 6 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hetrombopag
Number of subjects: 37
Study: 35282170

Group type: EXPERIMENTAL
Intervention: Premium Monovision Group (PmG) - implantation of trifocal diffractive Panoptix IOL in the non-dominant eye and bifocal hybrid refractive-diffractive Restor IOL in the dominant eye.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bilateral Myopic Monovision Group (MfG) - implantation of monofocal SN60WF IOL targeting -0.50 D in the dominant eye and -1.25 D myopia in the non-dominant eye.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hybrid Monovision Group (HmG) - implantation of Panoptix in the non-dominant eye and SN60WF in the dominant eye.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Bilateral Trifocal Implantation Group - bilateral Panoptix implantation.
Number of subjects: 120
Study: 35282383

Group type: EXPERIMENTAL
Intervention: Worsening left ventricular ejection fraction (LVEF) defined as an absolute decline ≥ 5% from baseline LVEF within 3 to 12 months after discharge.
Number of subjects: 1418

Group type: EXPERIMENTAL
Intervention: Baseline left ventricular end-diastolic dimension (LVEDD), LVEF, high-density lipoprotein cholesterol (HDL-C), atrial fibrillation (AF), and diabetes mellitus (DM) as predictors of worsening LVEF.
Number of subjects: 1418
Study: 35283064

Group type: EXPERIMENTAL
Intervention: Low LVEF1 group
Number of subjects: 644

Group type: COMPARATOR
Intervention: High LVEF1 group
Number of subjects: 644
Study: 35283104

Group type: EXPERIMENTAL
Intervention: benralizumab (30-mg subcutaneous dose)
Number of subjects: 29
Study: 35283158

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy
Number of subjects: 0
Study: 35283268

Group type: EXPERIMENTAL
Intervention: Internet-delivered psychological intervention for chronic pain
Number of subjects: 85
Study: 35283330

Group type: EXPERIMENTAL
Intervention: Benralizumab (anti-IL-5RA)
Number of subjects: 7
Study: 35283347

Group type: EXPERIMENTAL
Intervention: High early pregnancy body mass index
Number of subjects: 2363

Group type: COMPARATOR
Intervention: Class II or III obesity
Number of subjects: 2363
Study: 35283460

Group type: EXPERIMENTAL
Intervention: Alternative dosing forms of hydrocortisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen biosynthesis inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy vector
Number of subjects: 0
Study: 35283693

Group type: EXPERIMENTAL
Intervention: Prostate-specific membrane antigen- (PSMA-) targeted radioligand therapy (RLT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SUV parameters
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Volumetric parameters
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SUVs
Number of subjects: 21
Study: 35284589

Group type: EXPERIMENTAL
Intervention: Hip arthroscopic surgery
Number of subjects: 60
Study: 35284585

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Emotional distress
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Widespread pain
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Self-efficacy and emotional distress combined
Number of subjects: 112
Study: 35284909

Group type: EXPERIMENTAL
Intervention: POM mHealth app
Number of subjects: 43
Study: 35285015

Group type: EXPERIMENTAL
Intervention: Disulfiram (DSF) 3 mg/kg, every 3rd day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disulfiram (DSF) 10 mg/kg, every 3rd day
Number of subjects: 0

Group type: COMPARATOR
Intervention: β-aminopropionitrile (BAPN) 100 mg/kg, daily
Number of subjects: 0
Study: 35285405

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HF-RT) with nodal simultaneous integrated boost (nSIB) at a dose of 2.67 Gy x 15 fractions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (HF-RT) with nSIB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose-limiting toxicity (DLT)
Number of subjects: 0
Study: 35285484

Group type: EXPERIMENTAL
Intervention: Panitumumab, chemotherapy, and external beam radiation therapy
Number of subjects: 51
Study: 35285519

Group type: EXPERIMENTAL
Intervention: Brivaracetam add-on therapy
Number of subjects: 2411
Study: 35285747

Group type: EXPERIMENTAL
Intervention: Respiratory Therapists (RT)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Control group (physicians and nurses)
Number of subjects: 445
Study: 35285786

Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg BID for 4 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg BID for 5 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg BID with Maraviroc 300 mg BID for 7 days
Number of subjects: 14
Study: 35285810

Group type: EXPERIMENTAL
Intervention: Cognitive test battery including EEG-based assessments and MRI imaging
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cross-sectional data analysis
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Longitudinal data analysis
Number of subjects: 600
Study: 35285859

Group type: EXPERIMENTAL
Intervention: DASH diet adherence
Number of subjects: 2660

Group type: EXPERIMENTAL
Intervention: 5-point higher DASH score (range, 7 to 35)
Number of subjects: 2660
Study: 35285981

Group type: EXPERIMENTAL
Intervention: Tandem autologous stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35286612

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 595

Group type: COMPARATOR
Intervention: Topical/traditional systemic agents
Number of subjects: 595
Study: 35287034

Group type: EXPERIMENTAL
Intervention: Long-acting buprenorphine subcutaneous injection
Number of subjects: 216
Study: 35287119

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35287148

Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mind-wandering
Number of subjects: 59
Study: 35287171

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 162

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 162
Study: 35287469

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg once daily administered orally
Number of subjects: 0
Study: 35287613

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 260 mg/m²
Number of subjects: 261
Study: 35287672

Group type: EXPERIMENTAL
Intervention: Sandoz biosimilar filgrastim (twice-daily)
Number of subjects: 245
Study: 35287714

Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with Veterans and PC stakeholders
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Focus groups with PC providers and staff
Number of subjects: 25
Study: 35287719

Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal ischemic lesions (no lesions, moderate lesions, severe lesions)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Higher adrenaline dose during cardiopulmonary resuscitation
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Previous proton pump inhibitor use
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Serum bicarbonate on day 1
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Severe lesions
Number of subjects: 214
Study: 35287722

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (BMMNC) infusion
Number of subjects: 19
Study: 35287731

Group type: EXPERIMENTAL
Intervention: DASH diet with 85g of fresh lean beef
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DASH diet with 170g of fresh lean beef
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined beef intake groups
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 28
Study: 35287760

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 18
Study: 35287967

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg intravenously q4w and olaparib 300 mg 2dd until disease progression, unacceptable toxicity, or patient withdrawal
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Durvalumab and olaparib
Number of subjects: 55
Study: 35287972

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (overall)
Number of subjects: 89
Study: 35288144

Group type: EXPERIMENTAL
Intervention: Normal type
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Glaucoma-like defects
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: High myopia-related defects
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Combined defects
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: Interobserver and intraobserver agreement
Number of subjects: 1302
Study: 35288462

Group type: EXPERIMENTAL
Intervention: ZEB1 expression in melanoma cells
Number of subjects: 60
Study: 35288468

Group type: EXPERIMENTAL
Intervention: Itacitinib (100-400 mg once a day) plus epacadostat (50-300 mg two times per day)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Itacitinib (100-400 mg once a day) plus parsaclisib (0.3-10 mg once a day)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Itacitinib plus epacadostat
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Itacitinib plus parsaclisib
Number of subjects: 142
Study: 35288511

Group type: EXPERIMENTAL
Intervention: AI-graded BSS scores
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AI-graded daily average BSS scores
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AI stool characterization
Number of subjects: 39
Study: 35289117

Group type: EXPERIMENTAL
Intervention: Public assistance group
Number of subjects: 3728

Group type: COMPARATOR
Intervention: No public assistance group
Number of subjects: 3728
Study: 35289267

Group type: EXPERIMENTAL
Intervention: Positron emission tomography-computerised tomography
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced computerised tomography
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Combination of maximum standardised uptake value and peak enhancement
Number of subjects: 380
Study: 35289310

Group type: EXPERIMENTAL
Intervention: Antiphospholipid ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 0
Study: 35289316

Group type: EXPERIMENTAL
Intervention: NEMO-Δex5
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: TNF stimulation of dermal fibroblasts
Number of subjects: 3
Study: 35289329

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 25
Study: 35289396

Group type: EXPERIMENTAL
Intervention: ERAS programmes
Number of subjects: 747
Study: 35289662

Group type: EXPERIMENTAL
Intervention: Dynamic chest radiography (DCR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 0
Study: 35289694

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 47
Study: 35289736

Group type: EXPERIMENTAL
Intervention: BET Protein Inhibition
Number of subjects: 0
Study: 35289758

Group type: EXPERIMENTAL
Intervention: Self-managed educational and exercise-based mHealth intervention (BackFit app)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Face-to-face educational and exercise-based intervention
Number of subjects: 50
Study: 35289904

Group type: EXPERIMENTAL
Intervention: Ultrasound identification of the RMM's inferior margin
Number of subjects: 100
Study: 35289922

Group type: COMPARATOR
Intervention: Duct-to-mucosa pancreaticojejunostomy
Number of subjects: 1696

Group type: COMPARATOR
Intervention: Modified Blumgart technique
Number of subjects: 1696
Study: 35290073

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of fatigue trajectories
Number of subjects: 4173

Group type: EXPERIMENTAL
Intervention: Assessment of fatigue at diagnosis and year 1, 2, and 4 postdiagnosis
Number of subjects: 4173
Study: 35290075

Group type: EXPERIMENTAL
Intervention: Noncalcified plaque volume
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Coronary artery calcification score
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Calcified plaque volume
Number of subjects: 196
Study: 35290453

Group type: EXPERIMENTAL
Intervention: Concizumab 0.15 mg/kg (with potential dose escalation to 0.20 or 0.25 mg/kg)
Number of subjects: 61
Study: 35290461

Group type: EXPERIMENTAL
Intervention: School-based screening and treatment with artemether-lumefantrine
Number of subjects: 704
Study: 35290467

Group type: EXPERIMENTAL
Intervention: P. falciparum CS2 parasites infection during the third trimester
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent infections with P. falciparum CS2 parasites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple acute PM episodes and subsequent VAR2CSA immunization
Number of subjects: 0
Study: 35290624

Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 1091

Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 1091
Study: 35291289

Group type: EXPERIMENTAL
Intervention: 100-μg mRNA-1273 booster dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control group (second dose of mRNA-1273)
Number of subjects: 0
Study: 35291351

Group type: EXPERIMENTAL
Intervention: Metreleptin therapy
Number of subjects: 32
Study: 35291821

Group type: EXPERIMENTAL
Intervention: NIHSS conducted by paramedics
Number of subjects: 274

Group type: COMPARATOR
Intervention: NIHSS-trained paramedics
Number of subjects: 274
Study: 35291977

Group type: EXPERIMENTAL
Intervention: Lapatinib 1,250 mg orally once per day continuously plus capecitabine (1,000 mg/m2)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 159
Study: 35291998

Group type: EXPERIMENTAL
Intervention: Severe RSV infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 35292028

Group type: EXPERIMENTAL
Intervention: ICHOM-SSS implementation in stroke unit care
Number of subjects: 24
Study: 35292485

Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise intervention (20-week duration, including supervised and unsupervised exercise sessions)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise intervention
Number of subjects: 25
Study: 35292570

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 141
Study: 35292609

Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: TDM
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Dose adjustment based on TDM measurements
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Use of European Committee on Antimicrobial Susceptibility Testing's epidemiological cutoff values
Number of subjects: 209
Study: 35292700

Group type: EXPERIMENTAL
Intervention: Methylation at four GDF-15 related CpG sites (cg13033858, cg16936953, cg17150809, cg18608055)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Joint influences of cg16936953 and the score
Number of subjects: 19